ZEB1 and prostate carcinoma: Earlier studies revealed that the positive expression of ZEB1 in endometrial cancers, colorectal carcinomas, and hepatocellular and prostate cancer was associated with aggressive disease, poor differentiation, the development of metastases, and a poor clinical prognosis [20–22].